MPM BioVentures 2014, L.P. - 13 May 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Former 10% Owner
Signature
/s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.
Issuer symbol
ITOS
Transactions as of
13 May 2025
Net transactions value
-$5,079,339
Form type
4
Filing time
15 May 2025, 17:32:22 UTC
Previous filing
30 Apr 2025
Next filing
29 Oct 2025
SEC
View on sec.gov

Reporting Owners (9)

Name Relationship Address Signature Signature date CIK
MPM BioVentures 2014, L.P. Former 10% Owner C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P. 15 May 2025 0001609492
MPM BioVentures 2014 (B), L.P. Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P. 15 May 2025 0001609493
MPM Asset Management Investors BV2014 LLC Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, the Manager of MPM Asset Management Investors BV2014 LLC 15 May 2025 0001609495
MPM BioVentures 2014 GP LLC Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC 15 May 2025 0001765091
MPM BioVentures 2014 LLC Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC 15 May 2025 0001765021
MPM BIOVENTURES 2018 (B), L.P. Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2018 LLC, the Managing Member of MPM BioVentures 2018 GP LLC, the General Partner of MPM BioVentures 2018 (B), L.P. 15 May 2025 0001729504
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Ansbert Gadicke, Managing Director of MPM BioVentures 2018 LLC, the Manager of MPM Asset Management Investors BV2018 LLC 15 May 2025 0001734817
EVNIN LUKE Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Luke Evnin 15 May 2025 0001134657
Foley Todd Former 10% Owner C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Todd Foley 15 May 2025 0001473930

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale $5,079,339 -630,191 -23% $8.06 2,108,594 13 May 2025 See Footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

MPM BioVentures 2014, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P. for additional members of this joint filing.